ESC 2022: The ASCEND Trial: Aspirin and Omega-3 Fatty Acids in Preventing Heart Failure

Подробнее о видео

Watch on Radcliffe Cardiology: *c45wwx*_ga*MTE1NzYxMzg0NC4xNjYxNTg2ODk0*_ga_T874FCJ3LG*MTY2MTU4Njg5My4xLjEuMTY2MTU4ODQ5MC4wLjAuMA..&_ga=2.180858080.670019713.1661586894-1157613844.1661586894&utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-6605&utm_content=esc_goonasekera

In this short interview, Dr Michelle Goonasekera (University of Oxford, Oxford, UK) joins us on-site at the ESC congress to discuss the findings of the ASCEND Study (NCT00135226).

ASCEND aimed to evaluate the effects of 100mg daily aspirin on top of 1 gram of omega-3 fatty acids in the prevention of serious vascular events, including non-fatal heart attack, stroke and transient ischaemic attack. 15480 patients with diabetes mellitus were enrolled in the trial.

Questions:

-What is the importance of this study?
-What was the study design and what were the considerations around choosing the dosage of omega-3 (n3) fatty acid?
-What are the key results?
-What are the future directions for omega-3 fatty acids in prevention?
-What are the key take-home messages?

Recorded on-site at ESC 22, Barcelona.
Editor: Jordan Rance
Interviewer: Mirjam Boros
Videography: Tom Green, Dan Brent, Oliver Miles, Mike Knight

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.